Answers are grounded in this paper and cite their sources.
Uncovers FLT3LG's role in promoting regulatory-like CD4+ T cell features in breast cancer, suggesting a key immunoregulatory mechanism.
Regulatory and dysfunctional CD4 + T cell states contribute to immune evasion in breast cancer (BC), but the molecular programs associated with these phenotypes remain incompletely understood. Here, we identify FLT3 ligand (FLT3LG) as a γ-chain (γc) cytokine-responsive factor enriched in CD4 + T cells of BC. Public transcriptomic and scRNA-seq analyses showed that FLT3LG expression was linked to Treg-enriched immune regulatory signatures. In Jurkat T cells, FLT3LG overexpression (OE) increased regulatory markers and inhibitory receptors while reducing effector cytokine expression and proliferative capacity, consistent with a regulatory-like and reduced effector phenotype rather than bona fide Treg differentiation. In BC co-culture models, HER2 + BC cell lines induced FLT3LG and FOXP3 expression in Jurkat and primary human T cells. FLT3LG-OE T cells were further associated with increased Ki-67 expression and reduced apoptosis in co-cultured BC cells, as well as altered CFSE profiles of primary responder T cells. Mechanistically, γc cytokines induced FLT3LG expression through STAT5-dependent signaling. In a syngeneic mammary tumor model, FLT3LG expression increased in CD4 + T cells during tumor progression, particularly within the Treg subset. Consistently, clinical dataset analyses showed that high FLT3LG expression was associated with poor outcomes in HER2 + and highly proliferative BC contexts. Together, these findings reveal a γc cytokine-STAT5-FLT3LG regulatory circuit linked to CD4 + T cell immunoregulation in BC.
No takes yet. Share an insight, caveat, or question.
Im et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: